Stelara carries a list price of $25,497 for a single 90 mg dose, and patients on the standard maintenance schedule for Crohn’s disease or ulcerative colitis receive that dose every eight weeks. That puts the annual list price well above $150,000, making it one of the most expensive drugs in the U.S. The cost isn’t driven by any single factor but by a combination of biology, market positioning, patent strategy, and a pricing system that rewards high sticker prices.
Biologics Cost More to Make Than Pills
Stelara is a biologic drug, meaning it’s a large, complex molecule produced inside living cells rather than assembled through chemical reactions in a factory. Traditional pills are small molecules that can be synthesized cheaply and consistently. Biologics require mammalian cell cultures grown under tightly controlled conditions, followed by extensive purification steps to ensure the final product is pure, consistent, and active. Any slight variation in temperature, timing, or contamination can ruin an entire batch.
This complexity raises both the development cost and the ongoing production cost. The facilities themselves require specialized equipment and continuous quality monitoring that small-molecule manufacturing simply doesn’t need. None of this fully explains a $25,000-per-dose price tag, but it does set a higher cost floor than most people expect when they think about “making medicine.”
Decades of Clinical Trials Across Multiple Diseases
Stelara was first approved for moderate to severe plaque psoriasis, but Johnson & Johnson didn’t stop there. The company ran at least 11 major clinical trials to expand the drug’s approved uses to psoriatic arthritis, Crohn’s disease, ulcerative colitis, and pediatric psoriasis in children as young as six. Each new indication required its own set of large, multi-phase trials, sometimes two or three of them, to prove the drug was safe and effective for that specific condition.
That breadth is unusual. Most biologics target one or two conditions. Stelara’s range across skin, joint, and gastrointestinal diseases gave Johnson & Johnson a massive patient base, but also required an enormous upfront investment. Companies price drugs to recoup that R&D spending, and a drug with this many indications carries a proportionally large bill. It also means the drug serves patients who have few alternatives. For Crohn’s disease and ulcerative colitis, Stelara is the only drug in its class (IL-12/23 inhibitors) approved in the U.S., which limits competitive pressure on price.
Limited Competition Kept Prices High for Years
For psoriasis and psoriatic arthritis, several alternatives exist: drugs like Skyrizi, Tremfya, Cosentyx, and Taltz all compete in the same space. But Stelara remained the most widely used. In Colorado’s 2022 claims data, about 1,700 patients were on Stelara compared to roughly 1,000 each for Skyrizi and Taltz. Despite being the most utilized, Stelara also carried the highest out-of-pocket costs for commercially insured patients, averaging $5,875 per year compared to an average of $4,699 across its competitors.
Monthly out-of-pocket costs tell a similar story. Commercially insured patients on Stelara paid roughly $490 per month, compared to about $258 for Cosentyx and $236 for Taltz. Skyrizi and Tremfya landed closer to Stelara’s range, around $467 and $488 respectively. The fact that Stelara maintained its dominant market share despite costing more suggests that switching drugs in this category isn’t simple. Patients and doctors who find something that works are reluctant to change, which gives the manufacturer less reason to lower the price.
The Rebate System Inflates the Sticker Price
One of the least visible forces driving Stelara’s high list price is the rebate system. Insurance companies and pharmacy benefit managers (PBMs) negotiate discounts off the list price, and those rebates can be substantial. In a Colorado state affordability review, 72% of insurance carriers reported that Stelara was among the top 15 drugs for which they received the largest rebates. Six carriers ranked it first. Five ranked it second.
This means the amount Johnson & Johnson actually receives per dose is significantly less than the $25,497 sticker price. The company reported spending a large (though redacted) percentage of its gross Stelara sales on rebates, 340B program discounts, patient assistance programs, and other price concessions. The problem is that those rebates flow to insurers and PBMs, not necessarily to patients. Your copay or coinsurance is often calculated on the list price or a number close to it, so you can end up paying thousands while your insurer pockets a discount you never see. This creates a perverse incentive: a higher list price means larger rebates, which makes the drug more attractive for PBMs to include on their formularies, which drives even higher list prices over time.
Dosing Frequency Multiplies the Annual Bill
How much Stelara costs you per year depends heavily on what you’re taking it for. Patients with psoriasis or psoriatic arthritis receive a 45 mg injection every 12 weeks after the initial loading doses (90 mg if they weigh over 220 pounds). That works out to roughly four or five doses per year. Patients with Crohn’s disease or ulcerative colitis, however, receive a 90 mg injection every eight weeks, which means about six to seven doses per year at the higher strength. The difference in annual list-price exposure between those two schedules is tens of thousands of dollars.
Biosimilars and Government Negotiation Are Changing the Picture
Two major shifts are now pushing Stelara’s price downward. First, biosimilars (the biologic equivalent of generic drugs) began entering the U.S. market after patent settlements cleared the way. Amgen’s biosimilar launched with an 85% discount off Stelara’s list price. That kind of price drop signals how inflated the original price had become, though it will take time for biosimilars to gain widespread adoption as insurers update their formularies.
Second, Stelara was selected as one of the first 10 drugs for Medicare price negotiation under the Inflation Reduction Act. The negotiated price takes effect January 1, 2026, and will apply to Medicare Part D patients. The exact savings will depend on the final negotiated figure, but the selection itself reflects how much the government identified Stelara as a driver of unsustainable drug spending.
For patients currently paying high out-of-pocket costs, the practical effect of these changes will depend on insurance type. Medicare patients should see relief starting in 2026. Commercially insured patients may benefit as biosimilar competition forces broader price adjustments, though the timeline is less certain. Johnson & Johnson’s patient assistance programs remain an option in the interim for those struggling with costs, though eligibility varies.